Epigeneres

Epigeneres provides genomics-based diagnostic tests for cancer, developing innovative molecular diagnostic solutions that enable early detection and monitoring of cancer through genomic analysis. The company leverages advanced genomics technology to create diagnostic tests that help identify cancer at molecular levels, supporting clinicians in making informed treatment decisions and enabling personalized medicine approaches. Epigeneres operates in the genomics and diagnostics space, focusing on translating genomic research into clinically actionable diagnostic tools that can improve patient outcomes through earlier detection and more precise disease characterization. The company's technology aims to address the critical need for reliable, accessible cancer diagnostics that can detect disease before traditional symptoms appear, potentially enabling earlier intervention and improved survival rates. Founded in 2008 and headquartered in Mumbai, India, Epigeneres has raised $9.8M in Series B funding from investors including Torrent Pharma, HealthCare Global Enterprises, Kotak Investment Advisors, Kotak Mahindra Bank, LetsVenture, and East River Advisors.

Oncology > In-Vitro Diagnostic Tests > Pan Cancer,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Immuno-sequencing